Compare RVLV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | IBRX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2019 | N/A |
| Metric | RVLV | IBRX |
|---|---|---|
| Price | $30.82 | $2.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $27.08 | $9.71 |
| AVG Volume (30 Days) | 1.0M | ★ 13.5M |
| Earning Date | 02-24-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.78 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,195,039,000.00 | $82,555,000.00 |
| Revenue This Year | $8.95 | $667.18 |
| Revenue Next Year | $6.42 | $93.03 |
| P/E Ratio | $39.74 | ★ N/A |
| Revenue Growth | 9.24 | ★ 1025.95 |
| 52 Week Low | $16.80 | $1.83 |
| 52 Week High | $33.68 | $4.27 |
| Indicator | RVLV | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.37 | 60.13 |
| Support Level | $29.56 | $1.95 |
| Resistance Level | $31.68 | $2.29 |
| Average True Range (ATR) | 1.10 | 0.11 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 73.97 | 81.65 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.